Been watching this one pretty closely. Eli Lilly is absolutely crushing it right now with the GLP-1 hype, but something doesn't add up when you dig into the numbers.

Sure, the growth looks insane on paper. Mounjaro nearly doubled sales in 2025, and Zepbound jumped 175%. Eli has clearly won the GLP-1 race with better efficacy than what Novo Nordisk brought to market first. The market loves a winner, so the stock got bid up hard.

Here's where it gets interesting though. The valuation is wild - we're talking a P/E of 44 when the S&P 500 sits around 28 and pharma stocks average closer to 23. That's a lot of good news already priced in. And get this: these two drugs account for 56% of Eli Lilly's revenue and basically all the growth momentum.

The real issue? Pharma has a playbook we've seen play out before. Novo Nordisk was first to market and looked untouchable until Eli's superior product took share. Now what stops Pfizer or someone else from doing the same thing? The sector is competitive as hell.

But there's something even more concrete to worry about. Patents don't last forever. Fast forward 10 years and Eli could be facing generic competition on these blockbuster drugs. That's a revenue cliff nobody's really talking about. Even in the best case, this GLP-1 dominance has an expiration date.

I get that Eli is investing in pipeline development to hedge against this, but buying at these valuations means you're betting everything on sustained success. In a sector with this much history of disruption, that's a pretty aggressive bet for a decade-long hold. Definitely something to think about before jumping in.